MEMORANDUM # 30

TO: UNCHCS Attending Physicians and Faculty Practice Physicians, Housestaff, Clinical Nurse Coordinators, Department Heads and Supervisors

FROM: Karen Weck, MD, Medical Director, Molecular Genetics Laboratory

Jessica Booker, PhD, Scientific Director, Molecular Genetics Laboratory

Herbert C. Whinna, MD, PhD, Medical Director, McLendon Clinical Laboratories

SUBJECT: Method Change for Factor V Leiden (F5) and Factor II (F2) Mutation Testing

DATE: October 17, 2019

Effective immediately, the methodology for detection of the Factor V Leiden mutation (*F5*, c.1601G>A, p.Arg534Gln) and Factor II (*F2*, Prothrombin, c.*97G>A, 20210G>A) associated with increased risk of thrombosis has changed from a mutation-specific melting curve analysis to a TaqMan genotyping assay.

The change was made due to obsolescence of the instrumentation used for melting curve analysis and discontinuation of reagent kits by the manufacturer. There will be no change to reporting for these mutations. However, this assay will no longer identify the rare *F2* c.*96C>T variant of uncertain significance that was detected by the previous assay.

Specimen requirements remain unchanged, with 3 mL of blood in an ACD or EDTA tube. The assays are run once per week and turn-around time is 10 days.

If you have questions, please call the UNC Molecular Genetics Lab at (984) 974-1825 or contact Dr. Jessica Booker at (984) 974-1456. E-mail: Jessica.Booker@unchealth.unc.edu

Website, https://www.uncmedicalcenter.org/mclendon-clinical-laboratories/.